同和药业
(300636)
| 流通市值：25.75亿 | | | 总市值：29.44亿 |
| 流通股本：3.67亿 | | | 总股本：4.20亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 184,392,671.37 | 828,659,350.98 | 636,241,288.48 | 427,422,152.61 |
| 营业收入 | 184,392,671.37 | 828,659,350.98 | 636,241,288.48 | 427,422,152.61 |
| 二、营业总成本 | 167,876,632.18 | 702,520,673.31 | 520,768,052.25 | 341,667,938.34 |
| 营业成本 | 131,745,065.82 | 577,933,442.86 | 440,889,800.95 | 292,995,437.49 |
| 税金及附加 | 1,378,782.78 | 6,496,304.8 | 5,252,146.68 | 3,804,496.56 |
| 销售费用 | 6,186,641.62 | 28,918,363.5 | 19,980,796.6 | 11,531,947.55 |
| 管理费用 | 9,863,739.24 | 37,779,917.42 | 26,851,968.98 | 17,625,388.37 |
| 研发费用 | 15,512,609.13 | 64,993,391.22 | 41,033,872.63 | 26,648,811.91 |
| 财务费用 | 3,189,793.59 | -13,600,746.49 | -13,240,533.59 | -10,938,143.54 |
| 其中:利息费用 | 2,326,673.43 | 12,498,497.27 | 9,543,924.37 | 6,508,375.87 |
| 其中:利息收入 | - | 25,522,287.79 | 19,956,218.01 | 13,800,458.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 131,150 | 214,316.67 | 36,705.11 | 36,683.33 |
| 加:投资收益 | -452,504.61 | -1,116,706.88 | -747,741.82 | -280,829.37 |
| 资产处置收益 | 67,081.06 | -767,628.83 | -194,305.92 | -194,305.92 |
| 资产减值损失(新) | -225,175.73 | -62,190,491.59 | -31,639,391.53 | -26,621,114.78 |
| 信用减值损失(新) | -453,372.53 | -1,464,805.35 | -1,483,876.67 | -946,474.7 |
| 其他收益 | 4,032,776.52 | 14,081,023.53 | 10,290,433 | 6,833,409.14 |
| 四、营业利润 | 19,615,993.9 | 74,894,385.22 | 91,735,058.4 | 64,581,581.97 |
| 加:营业外收入 | - | 682,342.22 | 682,342.22 | 51.02 |
| 五、利润总额 | 19,615,993.9 | 75,576,727.44 | 92,417,400.62 | 64,581,632.99 |
| 减:所得税费用 | 836,491.19 | 2,485,294.13 | 8,752,809.58 | 6,095,120.42 |
| 六、净利润 | 18,779,502.71 | 73,091,433.31 | 83,664,591.04 | 58,486,512.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,779,502.71 | 73,091,433.31 | 83,664,591.04 | 58,486,512.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 18,779,502.71 | 73,091,433.31 | 83,664,591.04 | 58,486,512.57 |
| 扣除非经常损益后的净利润 | 16,064,332.56 | 62,744,675.49 | 76,288,014.46 | 53,686,419.63 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.17 | 0.2 | 0.14 |
| (二)稀释每股收益 | 0.04 | 0.17 | 0.2 | 0.14 |
| 九、综合收益总额 | 18,779,502.71 | 73,091,433.31 | 83,664,591.04 | 58,486,512.57 |
| 归属于母公司股东的综合收益总额 | 18,779,502.71 | 73,091,433.31 | 83,664,591.04 | 58,486,512.57 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-25 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |